Limits...
Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome.

Dispenzieri A, Lacy MQ, Hayman SR, Kumar SK, Buadi F, Dingli D, Litzow MR, Gastineau DA, Inwards DJ, Elliott MA, Micallef IN, Ansell SM, Hogan WJ, Porrata LF, Johnston PA, Afessa B, Bryce A, Kyle RA, Gertz MA - Eur. J. Haematol. (2008)

Bottom Line: Earlier and more aggressive use of corticosteroids may be associated with less complicated post-transplant courses.In addition, important clinical improvements and reductions in plasma VEGF levels can occur in the absence of significant decrease in the monoclonal protein.Unraveling the mechanisms of the syndrome both in the context of ASCT and in general are challenges for the future.

View Article: PubMed Central - PubMed

Affiliation: Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. dispenzieri.angela@mayo.edu

ABSTRACT
Polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes (POEMS) syndrome is a devastating syndrome, characterized by peripheral neuropathy, organomegaly, endocrinopathy, monoclonal plasma cells, skin changes, papilledema, volume overload, sclerotic bone lesions, thrombocytosis and high vascular endothelial growth factor (VEGF). High-dose chemotherapy with autologous peripheral blood stem cell transplantation (ASCT) ultimately yields excellent clinical responses, but there can be considerable peritransplant morbidity. We have treated 30 POEMS patients with ASCT at Mayo Clinic, Rochester. During transplant period, patients had high rates of fever, diarrhea, weight gain and rash (93%, 77%, 53% and 43%, respectively). Only 13% remained outpatient, and median time to discharge from hospital was transplant day 17 (range 0-175). Splenomegaly was the baseline factor that best predicted for a complicated peritransplant course. Depending on the definition used, approximately 50% of patients satisfied criteria for engraftment syndrome. Earlier and more aggressive use of corticosteroids may be associated with less complicated post-transplant courses. Median overall survival has not been reached; the treatment-related mortality was 3%. In addition, important clinical improvements and reductions in plasma VEGF levels can occur in the absence of significant decrease in the monoclonal protein. Unraveling the mechanisms of the syndrome both in the context of ASCT and in general are challenges for the future.

Show MeSH

Related in: MedlinePlus

Engraftment syndrome (ES): signs and definitions. (A) Timing of neutrophil engraftment relative to other ES entities. (B) ES definitions and rates. M-, ‘modified’ Spitzer and Maiolino engraftment definitions relax the 96 and 24 h neutrophil requirements; CS, corticosteroid; CTX, cyclophosphamide; M, cyclophosphamide mobilization; C, cyclophosphamide used for 2–3 cycles prior to coming to transplant; SCT, stem cell transplant patient number. Patients no. 1–11 are those previously reported.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2327207&req=5

fig01: Engraftment syndrome (ES): signs and definitions. (A) Timing of neutrophil engraftment relative to other ES entities. (B) ES definitions and rates. M-, ‘modified’ Spitzer and Maiolino engraftment definitions relax the 96 and 24 h neutrophil requirements; CS, corticosteroid; CTX, cyclophosphamide; M, cyclophosphamide mobilization; C, cyclophosphamide used for 2–3 cycles prior to coming to transplant; SCT, stem cell transplant patient number. Patients no. 1–11 are those previously reported.

Mentions: As shown in Fig. 1A, the classic symptoms of ES – fever, rash, diarrhea, non-cardiogenic pulmonary edema, weight gain – were prevalent in these patients, but the majority did not satisfy the time criteria tied to neutrophil recovery as proposed by Spitzer (10) or Maiolino et al. (11) (Fig. 1B). The time to the first complication consistent with ES was day +9 (IQR 8–11), whereas, the median time to neutrophil engraftment was day +16 (IQR 14.5–18).


Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome.

Dispenzieri A, Lacy MQ, Hayman SR, Kumar SK, Buadi F, Dingli D, Litzow MR, Gastineau DA, Inwards DJ, Elliott MA, Micallef IN, Ansell SM, Hogan WJ, Porrata LF, Johnston PA, Afessa B, Bryce A, Kyle RA, Gertz MA - Eur. J. Haematol. (2008)

Engraftment syndrome (ES): signs and definitions. (A) Timing of neutrophil engraftment relative to other ES entities. (B) ES definitions and rates. M-, ‘modified’ Spitzer and Maiolino engraftment definitions relax the 96 and 24 h neutrophil requirements; CS, corticosteroid; CTX, cyclophosphamide; M, cyclophosphamide mobilization; C, cyclophosphamide used for 2–3 cycles prior to coming to transplant; SCT, stem cell transplant patient number. Patients no. 1–11 are those previously reported.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2327207&req=5

fig01: Engraftment syndrome (ES): signs and definitions. (A) Timing of neutrophil engraftment relative to other ES entities. (B) ES definitions and rates. M-, ‘modified’ Spitzer and Maiolino engraftment definitions relax the 96 and 24 h neutrophil requirements; CS, corticosteroid; CTX, cyclophosphamide; M, cyclophosphamide mobilization; C, cyclophosphamide used for 2–3 cycles prior to coming to transplant; SCT, stem cell transplant patient number. Patients no. 1–11 are those previously reported.
Mentions: As shown in Fig. 1A, the classic symptoms of ES – fever, rash, diarrhea, non-cardiogenic pulmonary edema, weight gain – were prevalent in these patients, but the majority did not satisfy the time criteria tied to neutrophil recovery as proposed by Spitzer (10) or Maiolino et al. (11) (Fig. 1B). The time to the first complication consistent with ES was day +9 (IQR 8–11), whereas, the median time to neutrophil engraftment was day +16 (IQR 14.5–18).

Bottom Line: Earlier and more aggressive use of corticosteroids may be associated with less complicated post-transplant courses.In addition, important clinical improvements and reductions in plasma VEGF levels can occur in the absence of significant decrease in the monoclonal protein.Unraveling the mechanisms of the syndrome both in the context of ASCT and in general are challenges for the future.

View Article: PubMed Central - PubMed

Affiliation: Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. dispenzieri.angela@mayo.edu

ABSTRACT
Polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes (POEMS) syndrome is a devastating syndrome, characterized by peripheral neuropathy, organomegaly, endocrinopathy, monoclonal plasma cells, skin changes, papilledema, volume overload, sclerotic bone lesions, thrombocytosis and high vascular endothelial growth factor (VEGF). High-dose chemotherapy with autologous peripheral blood stem cell transplantation (ASCT) ultimately yields excellent clinical responses, but there can be considerable peritransplant morbidity. We have treated 30 POEMS patients with ASCT at Mayo Clinic, Rochester. During transplant period, patients had high rates of fever, diarrhea, weight gain and rash (93%, 77%, 53% and 43%, respectively). Only 13% remained outpatient, and median time to discharge from hospital was transplant day 17 (range 0-175). Splenomegaly was the baseline factor that best predicted for a complicated peritransplant course. Depending on the definition used, approximately 50% of patients satisfied criteria for engraftment syndrome. Earlier and more aggressive use of corticosteroids may be associated with less complicated post-transplant courses. Median overall survival has not been reached; the treatment-related mortality was 3%. In addition, important clinical improvements and reductions in plasma VEGF levels can occur in the absence of significant decrease in the monoclonal protein. Unraveling the mechanisms of the syndrome both in the context of ASCT and in general are challenges for the future.

Show MeSH
Related in: MedlinePlus